The arrival of next-generation products is favouring the growth of global market for atopic dermatitis treatment. In last December, two new classes of drugs were introduced in the market that can be used for treating mild, moderate and even severe atopic dermatitis condition. Therefore, availability of more numbers of drugs give both physicians and patients wider options to select from. Also, some of the latest drugs carry much lower risks of side-effects. In addition, drugs like the calcineurin inhibitors no longer have patent protection, which allow manufacturing of its generic version that will be available at lower process in the market. Approval of Eucrisa (crisaborole) an ointment for mild to moderate eczema (atopic dermatitis) treatment by the U.S. FDA last year was also seen as massive achievement. According to Future Market Insights’ latest report, the global market for atopic dermatitis is set to reach a valuation of US$ 7,225 Mn by 2017-end, this figure is likely to grow to US$ 24,000 Mn by the end of 2027. The report further cites that the market will register a compound annual growth rate of over 12% between 2017 and 2027. This impressive growth is primarily owing to increasing prevalence of atopic dermatitis is various parts of the world.
A number of companies that are currently operating in the global market for atopic dermatitis are emphasizing on collaboration with other companies for developing products and drugs. For instance, a leading pharmaceutical company Allergan plc which is headquarter in Coolock, Republic of Ireland has recently acquired the US-based Vitae Pharmaceuticals, Inc., – a clinical-stage biopharmaceutical company that specializes in developing treatments for dermatologic conditions. The acquisition of the new company has allowed Allergan to add special developmental compounds to its medical dermatology pipeline.
Although the market for atopic dermatitis exhibits lucrative growth opportunities, high costs and severe risks of side effects with regards to biologic therapy remains major impediments of the market. Use of Dupixent can sometimes lead to side effects such as serious vision problems (keratitis) and pink eye (conjunctivitis) other allergic reactions. Few of the common side effects also include cold sores in the mouth, injection site reactions eye and eyelid inflammation, swelling, itching and even redness. In addition, Dupixent is quite an expensive biologic therapy.
North America at Forefront of Global Market for Atopic Dermatitis Treatment
In terms of revenue, the market in North America is likely to account for significant value share in 2017 and this trend is expected to continue over the next couple of years. Owing to existence of established healthcare infrastructure, the market in the region is expected to remain relatively more attractive. Revenues from the market in North America is projected to expand at a CAGR of 16% during 2017 to 2027 and stand at US$ 10,000 Mn by the end of 2027. Meanwhile, Western Europe holds the second position and is likely to reach a valuation is excess of US$ 7800 Mn by 2027, reflecting a robust CAGR of 14%.
Requesst a Sample Report with Table of Contents: https://www.futuremarketinsights.com/reports/sample/rep-gb-3097